Jaime is counsel in Ropes & Gray’s global litigation and enforcement practice group. Companies, boards, and senior executives rely on her to guide them through government enforcement actions, sensitive internal investigations, and other high-stakes civil and criminal matters. She is a trusted strategic advisor with a detailed knowledge of her clients’ businesses. Her counsel goes beyond the immediate legal question to the operational, commercial, and reputational considerations that matter most to the enterprise.

Clients call on Jaime when the stakes are highest. In a crisis, she assesses risk quickly, sets a clear and decisive course, and gives senior leaders the guidance they need to act with confidence.

Jaime’s practice is concentrated in the life sciences and healthcare sectors. She represents pharmaceutical, medical device, and healthcare services companies, as well as private equity sponsors and their portfolio companies, in government and internal investigations of alleged health care fraud and improper promotional practices. Her work spans the False Claims Act (FCA), the Anti-Kickback Statute (AKS), the Federal Food, Drug, and Cosmetic Act (FDCA), and the Foreign Corrupt Practices Act (FCPA).

Before joining Ropes & Gray, Jaime served as a Special Assistant Corporation Counsel at the New York City Law Department. There, she represented the City of New York and its agencies in federal and state litigation, defending city policies and practices against constitutional challenges.

Experience

False Claims Act & Health Care Fraud

  • Represented a global medical device manufacturer in connection with several matters, including negotiating a deferred prosecution agreement with the U.S. Department of Justice (DOJ) involving FDCA violations and litigation matters involving alleged FCA violations, consumer fraud, false advertising, products liability, and securities fraud.
  • Represented a global pharmaceutical company in an investigation by the U.S. Attorney’s Office (USAO) for the Southern District of New York (SDNY) focused on alleged violations of the federal FCA.
  • Represented a nationwide provider of in-home comprehensive health assessments for Medicare Advantage beneficiaries in FCA investigations out of the SDNY and Eastern District of Texas (EDTX). Negotiated a complex global resolution that included an unprecedentedly narrow corporate integrity agreement.
  • Represented a dental services organization in a civil FCA investigation by the USAO involving allegations of unlawful billing at affiliated practices, including claims submitted by doctors not yet credentialed with managed Medicaid programs at the time of service. Successfully resolved the matter with a low-dollar no-admission settlement.
  • Representing a major biopharmaceutical company in multiple investigations out of DOJ and the USAO for the SDNY regarding concerns that remuneration offered and paid in connection with speaker programs and advisory boards may have violated the AKS. Worked with the company to conduct an internal review and coordinate individual representation for former company employees and vendors who were contacted by government case agents.
  • Representing an Institutional Review Board provider in connection with an investigation related to clinical trials by the Criminal Division of the USAO for the SDNY.
  • Represented a managed long-term care plan in a high-profile fraud investigation conducted by the New York State Attorney General’s Medicaid Fraud Control Unit and the USAO for the SDNY.
  • Represented a U.S.-based applied behavior analysis provider in an investigation by the USAO for the Southern District of Indiana involving alleged improper TRICARE and Medicaid billing practices. Successfully advocated for a criminal declination and an expedited civil FCA settlement, avoiding a corporate integrity agreement for the company.
  • Representing a major home healthcare provider in responding to a DOJ CID about a transaction related to potential AKS violations.
  • Representing a private equity sponsor in a DOJ investigation of its portfolio company over alleged failures to oversee third-party agencies that improperly marketed health insurance plans and enrolled unqualified individuals amid heightened scrutiny of Affordable Care Act enrollment practices.
  • Investigated and negotiated resolutions of three FCA qui tam complaints for a physician practice management organization in connection with an investigation conducted by the USAO for the Eastern District of North Carolina.
  • Representing a medical equipment supplier and one of its sales representatives in responding to a CID out of the USAO for the Northern District of Ohio, concerning the Company’s relationship with a healthcare provider entity.

Public Corruption

  • Represented telecommunications company executives in two high-profile public corruption investigations and the resulting federal trials in Chicago. Negotiated no criminal charges and full immunity for a former senior executive, and prepared the executive and another former employee to testify at the trials of a former company president and former Speaker of the House Michael Madigan.
  • Represented a former high-ranking executive at a global professional services firm in a high-profile anti-corruption investigation relating to allegations of corruption and misconduct in South Africa.
  • Advised the board of directors for a private importer and distributor of energy solutions based in Mexico in connection with a DOJ inquiry regarding potential political corruption by a member of the U.S. Congress.

Anti-Corruption/International Risk

  • Represented a multinational healthcare company in parallel investigations out of the SEC and DOJ involving allegations of potentially improper business practices by the company’s third-party agents in Saudi Arabia, resulting in complete walkaways from the government.
  • Represented a leading multinational medical device company in connection with multiple internal and government investigations across global markets, obtaining complete walkaways from both DOJ and SEC.
  • Conducted several internal investigations of alleged violations of the FCPA, including for an international pharmaceutical manufacturer in China and an India-based subsidiary of a global venture capital firm.

Areas of Practice